Drug Trial Radar · NCT07535931
Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Systemic Sclerosis
Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
21
Planned (sponsor's estimate)
Start
Apr 10, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Shenzhen Huishan Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Southern Medical University, China
- First posted
- Apr 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection(HS\_SW01 Cells injection) in patients with systemic sclerosis, and to further explore its pharmacokinetics(PK), immunological profile and preliminary efficacy. Participants will be required to sign the informed consent form and will only be assigned to the study and enrolled after undergoing a series of tests and meeting the inclusion and exclusion criteria of the protocol.
Conditions
- Systemic Sclerosis (SSc)
Interventions
HS_SW01 cells injectionDrug
A single dose of 0.5×10⁶ cells/kg of HS\_SW01 cells injection will be given by intravenous infusion.
HS_SW01 cells injectionDrug
A single dose of 1×10⁶ cells/kg of HS\_SW01 cells injection will be given by intravenous infusion.
HS_SW01 cells injectionDrug
A single dose of 2×10⁶ cells/kg of HS\_SW01 cells injection will be given by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of DLTTime frame: Within 28 Days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.